BIIB

Biogen Idec Inc. Press Releases

$321.67
*  
5.61
1.77%
Get BIIB Alerts
*Delayed - data as of Oct. 24, 2014  -  Find a broker to begin trading BIIB now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases
10/23/2014 7:30:00 AM - Business Wire
▲3.93 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Whirlpool Corporation Appoints New Vice Chairmen In Expanded Roles
10/22/2014 10:00:00 AM - PR Newswire


Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5 Billion
10/22/2014 7:00:00 AM - Business Wire
▼-2.82 % Price Change since this news event. The Volume Ratio is 4.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals
10/15/2014 8:00:00 AM - Business Wire
▲6.66 % Price Change since this news event. The Volume Ratio is 1.57.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
10/8/2014 4:01:00 PM - Business Wire
▼-0.90 % Price Change since this news event. The Volume Ratio is 1.12.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
9/25/2014 5:34:00 PM - Business Wire


Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index
9/23/2014 8:00:00 AM - Business Wire


Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy
9/23/2014 7:00:00 AM - Business Wire


Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)
9/12/2014 7:30:00 AM - Business Wire


New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients
9/11/2014 7:30:00 AM - Business Wire


PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients
9/11/2014 7:30:00 AM - Business Wire


New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms
9/10/2014 7:00:00 AM - Business Wire


RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
9/4/2014 5:00:00 AM - Business Wire


Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care
9/3/2014 8:00:00 AM - Business Wire


Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014
9/2/2014 4:01:00 PM - Business Wire


Biogen Idec in Panel at the Citi 9th Annual Biotech Conference
8/26/2014 4:01:00 PM - Business Wire


Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub
8/26/2014 8:00:00 AM - Business Wire


Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
8/21/2014 7:00:00 AM - Business Wire


Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
8/15/2014 6:44:00 PM - Business Wire


Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
8/5/2014 8:00:00 AM - PR Newswire


RBCC 3D Bioprinting Partner Awarded Prestigious Grant
7/31/2014 6:54:00 AM - Business Wire